Retatrutide
Triple agonist (GLP-1, GIP, glucagon) studied in metabolic trials.
Evidence Level
Emerging
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Triple agonist (GLP-1, GIP, glucagon) studied in metabolic trials.
/ 02
Mechanism of Action
Studied for triple incretin/glucagon receptor activation.
/ 03
Research Applications
Body weight, energy expenditure research.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
Retatrutide is a triple agonist studied at the GIP, GLP-1, and glucagon receptors. Research describes combined effects on insulin secretion, appetite and caloric intake, and energy expenditure-related signaling through glucagon receptor activity.
/ 08
Pathway Role
Sits within an extended incretin and glucagon signaling pathway, combining appetite-regulating incretin activity with glucagon-mediated energy expenditure signaling.
/ 09
Biological Targets
/ 10
Research Applications
- Obesity clinical research
- Type 2 diabetes clinical research
- Hepatic steatosis research
- Cardiometabolic endpoint exploration
/ 11
Evidence Summary
Emerging but high-quality clinical development data exists from Phase 2 trials. Larger and longer outcome studies are ongoing.
Evidence Level Rationale
Rated emerging because controlled clinical trials exist but the long-term outcome and safety dataset is still developing.
/ 12
Research Observation Timeline
Early Signal Window
Metabolic and weight-related signals within weeks
Primary Study Window
Phase 2 study used 24-week primary endpoint and 48-week secondary endpoint
Endpoint Type
Clinical outcome endpoints (body weight, glycemic, hepatic)
Evidence Strength
Emerging clinical
/ 13
Safety & Unknowns
Gastrointestinal adverse events have been documented as common and dose-related in trials. Long-term safety profile is still being characterized.
/ 14
Research Limitations
Outcome data is primarily Phase 2; long-term and broad-population outcomes are not fully established.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Emerging
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
Semaglutide
GLP-1 receptor agonist studied for glycemic and weight research.
Tirzepatide
Dual GIP/GLP-1 agonist studied in metabolic research.
AOD-9604
Fragment of hGH (176-191) studied in lipid metabolism research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.